<DOC>
	<DOCNO>NCT01764607</DOCNO>
	<brief_summary>Solid organ transplant recipient ( SOTR ) 3-5x increased occurrence cancer contrast general population basal squamous cell skin cancer . The use immunosuppressant anti-rejection drug need SOTR known increase risk develop certain kind cancer . The purpose study find well Sirolimus ( also know Rapamune ) work treat squamous cell carcinoma renal transplant patient .</brief_summary>
	<brief_title>Sirolimus Kidney Transplant Patients With Squamous Cell Skin Carcinoma</brief_title>
	<detailed_description>This Phase II randomize study evaluate effectiveness Sirolimus treat prevent squamous cell skin cancer carcinoma use Simon 's 2-stage design . As part study , biopsy result skin cancer show squamous cell carcinoma consent obtain , participant begin take Sirolimus . The calcineurin inhibitor ( tacrolimus cyclosporine ) discontinue transplant doctor find participant Sirolimus therapeutic checking blood test week x 3 week . Approximately 5 week start Sirolimus , squamous cell skin cancer remove surgeon . Participant next follow visit study schedule one year post-operatively . .The study look squamous cell skin cancer microscope see sirolimus effect treat squamous cell skin cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically cytologically proven squamous cell skin carcinoma Recipient renal organ transplant least one year prior study enrollment Receiving CNI least 6 month prior diagnosis skin cancer No current evidence graft rejection , except lowgrade , chronic graft rejection Measurable disease caliper measurement Life expectancy &gt; 6 month Age least 18 year Adequate organ marrow function determine ANC , HGB , PLT , Total Bili , AST , creatinine clearance Ability understand/willingness sign write informed consent form Inability give inform consent Major surgery within 4 week prior start study drug Chronic nonhealing open wound Pregnant nursing woman Women men childbearing potential must agree use adequate contraception prior study entry study duration Prior use mTOR inhibitor Preexisting clinically significant cardiac , hepatic , pulmonary , renal dysfunction HIVpositive patient Proteinuria ( &gt; 1 gram ) Prior current history uncontrolled hyperlipidemia ( cholesterol &gt; 302 mg/dl triglyceride 354 mg/dl Currently receive investigational agent History allergic reaction attribute compound similar chemical biologic composition sirolimus ( mTOR inhibitor ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Squamous</keyword>
	<keyword>Renal</keyword>
	<keyword>Transplant</keyword>
</DOC>